ArticleHeliyon2024
An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment.
Jie Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.